Shockwave Medical Inc (NASDAQ:SWAV) insider Isaac Zacharias sold 4,000 shares of Shockwave Medical stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $40.24, for a total value of $160,960.00. Following the completion of the sale, the insider now owns 9,000 shares in the company, valued at $362,160. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Isaac Zacharias also recently made the following trade(s):
- On Monday, November 11th, Isaac Zacharias sold 4,000 shares of Shockwave Medical stock. The stock was sold at an average price of $35.66, for a total value of $142,640.00.
- On Friday, October 11th, Isaac Zacharias sold 4,000 shares of Shockwave Medical stock. The stock was sold at an average price of $32.68, for a total value of $130,720.00.
Shares of SWAV traded up $2.18 on Thursday, reaching $43.99. The stock had a trading volume of 819,615 shares, compared to its average volume of 447,484. The company has a current ratio of 6.76, a quick ratio of 6.28 and a debt-to-equity ratio of 0.09. The company has a 50-day simple moving average of $36.92 and a 200-day simple moving average of $42.99. Shockwave Medical Inc has a 12-month low of $24.58 and a 12-month high of $68.39.
Shockwave Medical (NASDAQ:SWAV) last released its earnings results on Thursday, November 7th. The company reported ($0.46) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.51) by $0.05. The firm had revenue of $11.33 million during the quarter, compared to analysts’ expectations of $10.42 million. The business’s revenue was up 214.7% on a year-over-year basis. Equities research analysts predict that Shockwave Medical Inc will post -2.03 earnings per share for the current fiscal year.
A number of equities research analysts have recently weighed in on SWAV shares. Oppenheimer began coverage on Shockwave Medical in a research report on Tuesday, October 22nd. They issued a “market perform” rating on the stock. Piper Jaffray Companies raised their target price on Shockwave Medical from $43.00 to $46.00 and gave the company an “overweight” rating in a research note on Wednesday. ValuEngine cut Shockwave Medical from a “buy” rating to a “hold” rating in a research note on Thursday, November 14th. Wells Fargo & Co upgraded Shockwave Medical from a “market perform” rating to an “overweight” rating and set a $49.00 target price for the company in a research note on Thursday. Finally, Canaccord Genuity lowered their target price on Shockwave Medical from $65.00 to $49.00 and set a “buy” rating for the company in a research note on Friday, November 8th. One analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company’s stock. Shockwave Medical currently has an average rating of “Hold” and an average target price of $44.00.
Several institutional investors and hedge funds have recently added to or reduced their stakes in SWAV. Wealthcare Advisory Partners LLC purchased a new position in shares of Shockwave Medical in the 3rd quarter valued at approximately $30,000. Salomon & Ludwin LLC purchased a new position in Shockwave Medical during the second quarter valued at $43,000. Advisor Group Inc. purchased a new position in Shockwave Medical during the second quarter valued at $56,000. Benjamin F. Edwards & Company Inc. raised its stake in Shockwave Medical by 244.0% during the third quarter. Benjamin F. Edwards & Company Inc. now owns 1,875 shares of the company’s stock valued at $56,000 after buying an additional 1,330 shares during the last quarter. Finally, Ladenburg Thalmann Financial Services Inc. raised its stake in Shockwave Medical by 1,350.0% during the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,450 shares of the company’s stock valued at $83,000 after buying an additional 1,350 shares during the last quarter. Institutional investors own 58.43% of the company’s stock.
About Shockwave Medical
ShockWave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters or treating below-the-knee peripheral artery disease.
Read More: Is a Roth IRA right for you?
Receive News & Ratings for Shockwave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shockwave Medical and related companies with MarketBeat.com's FREE daily email newsletter.